Wolverine Trading, LLC Neurocrine Biosciences Inc Transaction History

Wolverine Trading, LLC

$94.2 Billion
Q2 2024

A detailed history of Wolverine Trading, LLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Wolverine Trading, LLC holds 3,915 shares of NBIX stock, worth $491,371. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,915

Previous 6,860 42.93%

Holding current value

$491,371

Previous $946,000 43.13%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$130.86 - $143.19 $385,382 - $421,694	-2,945 Reduced 42.93%	3,915 $538,000
Q1 2024 May 15, 2024	BUY	$130.4 - $143.74 $894,544 - $986,056	6,860 New	6,860 $946,000
Q1 2022 May 16, 2022	BUY	$72.45 - $94.81 $16,735 - $21,901	231 Added 5.09%	4,768 $441,000
Q3 2021 Nov 12, 2021	BUY	$86.18 - $99.03 $130,821 - $150,327	1,518 Added 50.28%	4,537 $428,000
Q2 2021 Aug 06, 2021	BUY	$89.43 - $102.27 $41,227 - $47,146	461 Added 18.02%	3,019 $293,000
Q1 2021 May 14, 2021	SELL	$87.57 - $119.4 $287,842 - $392,467	-3,287 Reduced 56.24%	2,558 $241,000
Q4 2020 Feb 12, 2021	SELL	$86.91 - $108.33 $49,277 - $61,423	-567 Reduced 8.84%	5,845 $558,000
Q3 2020 Nov 13, 2020	SELL	$96.16 - $135.15 $186,550 - $262,191	-1,940 Reduced 23.23%	6,412 $626,000
Q1 2020 May 11, 2020	BUY	$75.11 - $113.76 $277,306 - $420,001	3,692 Added 79.23%	8,352 $765,000
Q4 2018 Feb 14, 2019	SELL	$68.32 - $124.36 $474,140 - $863,058	-6,940 Reduced 59.83%	4,660 $319,000
Q3 2018 Nov 14, 2018	BUY	$98.88 - $125.85 $1.15 Million - $1.46 Million	11,600 New	11,600 $1.43 Million

Others Institutions Holding NBIX

# of Institutions

629

Shares Held

94.2M

Call Options Held

692K

Put Options Held

406K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wolverine Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Wolverine Trading, LLC with notifications on news.

Account

Wolverine Trading, LLC Neurocrine Biosciences Inc Transaction History